Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2014 Aug 01;17116:3868-80. doi: 10.1111/bph.12748.
Show Gene links
Show Anatomy links
Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors.
Arimany-Nardi C
,
Errasti-Murugarren E
,
Minuesa G
,
Martinez-Picado J
,
Gorboulev V
,
Koepsell H
,
Pastor-Anglada M
.
???displayArticle.abstract???
BACKGROUND AND PURPOSE: Inhibitors of DNA methyltransferases (DNMTs), such as azacytidine, decitabine and zebularine, are used for the epigenetic treatment of cancer. Their action may depend upon their translocation across the plasma membrane. The aim of this study was to identify transporter proteins contributing to DNMT inhibitor action.
EXPERIMENTAL APPROACH: Drug interactions with selected hCNT and hENT proteins were studied in transiently transfected HeLa and MDCK cells. Interaction with human organic cation transporters (hOCTs) was assessed in transiently transfected HeLa cells and Xenopus laevis oocytes.
KEY RESULTS: Zebularine uptake was mediated by hCNT1, hCNT3 and hENT2. Decitabine interacted with but was not translocated by any nucleoside transporter (NT) type. hCNT expression at the apical domain of MDCK cells promoted net vectorial flux of zebularine. Neither hOCT1 nor hOCT2 transported decitabine, but both were involved in the efflux of zebularine, suggesting these proteins act as efflux transporters. hOCT1 polymorphic variants, known to alter function, decreased zebularine efflux.
CONCLUSIONS AND IMPLICATIONS: This study highlights the influence of human NTs and hOCTs on the pharmacokinetics and pharmacodynamics of selected DNMT inhibitors. As hOCTs may also behave as efflux transporters, they could contribute either to chemoresistance or to chemosensitivity, depending upon the nature of the drug or combination of drugs being used in cancer therapy.
Alexander,
The Concise Guide to PHARMACOLOGY 2013/14: transporters.
2013, Pubmed
Alexander,
The Concise Guide to PHARMACOLOGY 2013/14: transporters.
2013,
Pubmed
Arndt,
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
2001,
Pubmed
,
Xenbase
Bhutia,
CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.
2011,
Pubmed
Bock,
Nucleoside transporters are widely expressed in ovarian carcinoma effusions.
2012,
Pubmed
Cano-Soldado,
Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition.
2012,
Pubmed
Cano-Soldado,
Functional analysis of the human concentrative nucleoside transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket.
2012,
Pubmed
Chang,
Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1.
2004,
Pubmed
Damaraju,
Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.
2012,
Pubmed
,
Xenbase
Errasti-Murugarren,
Drug transporter pharmacogenetics in nucleoside-based therapies.
2010,
Pubmed
Errasti-Murugarren,
Different N-terminal motifs determine plasma membrane targeting of the human concentrative nucleoside transporter 3 in polarized and nonpolarized cells.
2010,
Pubmed
Errasti-Murugarren,
The human concentrative nucleoside transporter-3 C602R variant shows impaired sorting to lipid rafts and altered specificity for nucleoside-derived drugs.
2010,
Pubmed
Errasti-Murugarren,
Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs.
2007,
Pubmed
Farré,
Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors.
2004,
Pubmed
Fernández-Calotti,
Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.
2012,
Pubmed
Fernández-Calotti,
All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.
2010,
Pubmed
Garcia-Manero,
Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
2012,
Pubmed
Ghai,
Current approaches to epigenetic therapy for the treatment of mantle cell lymphoma.
2013,
Pubmed
Gong,
Metformin pathways: pharmacokinetics and pharmacodynamics.
2012,
Pubmed
Gorboulev,
Cloning and characterization of two human polyspecific organic cation transporters.
1997,
Pubmed
,
Xenbase
Govindarajan,
Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.
2008,
Pubmed
Govindarajan,
In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta.
2007,
Pubmed
Gupta,
Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel.
2012,
Pubmed
Harris,
Taurocholate transport by hepatic and intestinal bile acid transporters is independent of FIC1 overexpression in Madin-Darby canine kidney cells.
2004,
Pubmed
Heyn,
DNA methylation profiling in the clinic: applications and challenges.
2012,
Pubmed
Hollenbach,
A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
2010,
Pubmed
Hummel-Eisenbeiss,
The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.
2013,
Pubmed
Koepsell,
Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications.
2007,
Pubmed
Mangravite,
Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney.
2003,
Pubmed
Martinez-Becerra,
No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.
2012,
Pubmed
Mata,
Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
2001,
Pubmed
,
Xenbase
Minematsu,
Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.
2011,
Pubmed
Minuesa,
Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.
2008,
Pubmed
Minuesa,
Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.
2009,
Pubmed
Minuesa,
Drug uptake transporters in antiretroviral therapy.
2011,
Pubmed
Molina-Arcas,
Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.
2003,
Pubmed
Molina-Arcas,
Nucleoside transporter proteins.
2009,
Pubmed
Muñoz,
Epigenetic alterations involved in cancer stem cell reprogramming.
2012,
Pubmed
Pastor-Anglada,
SLC28 genes and concentrative nucleoside transporter (CNT) proteins.
2008,
Pubmed
Quintás-Cardama,
Therapy with azanucleosides for myelodysplastic syndromes.
2010,
Pubmed
Rius,
Epigenetic cancer therapy: rationales, targets and drugs.
2012,
Pubmed
Rius,
Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation.
2009,
Pubmed
Rius,
Vectorial transport of nucleoside analogs from the apical to the basolateral membrane in double-transfected cells expressing the human concentrative nucleoside transporter hCNT3 and the export pump ABCC4.
2010,
Pubmed
Robak,
New nucleoside analogs for patients with hematological malignancies.
2011,
Pubmed
Rodríguez-Mulero,
Expression of concentrative nucleoside transporters SLC28 (CNT1, CNT2, and CNT3) along the rat nephron: effect of diabetes.
2005,
Pubmed
Schaeffeler,
DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma.
2011,
Pubmed
Schmiedel,
Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation.
2011,
Pubmed
Shu,
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.
2007,
Pubmed
Shu,
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.
2008,
Pubmed
Shu,
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1.
2003,
Pubmed
,
Xenbase
Tzvetkov,
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
2009,
Pubmed
Volk,
Five amino acids in the innermost cavity of the substrate binding cleft of organic cation transporter 1 interact with extracellular and intracellular corticosterone.
2009,
Pubmed
,
Xenbase
Zhou,
Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases.
2002,
Pubmed
del Santo,
Differential expression and regulation of nucleoside transport systems in rat liver parenchymal and hepatoma cells.
1998,
Pubmed
